EC Dental Science

Mucopolysaccharidosis type IV (MPS IV), also known as Morquio syndrome, is a rare inherited metabolic disorder that affects the body and ability to break down certain types of complex sugars. It leads to the buildup of these substances in various tissues and organs, resulting in skeletal abnormalities, joint problems, heart and breathing difficulties, vision and hearing impairment, and other health issues. Symptoms and severity can vary widely among affected individuals. Treatment typically focuses on managing symptoms and providing supportive care. Dental treatment for individuals with Morquio syndrome requires careful consideration due to the unique challenges presented by the condition, such as skeletal abnormalities, dental abnormalities, and potential airway complications. A thorough evaluation of the patient and dental and skeletal issues is essential before any dental procedures. This assessment helps in understanding the extent of dental abnormalities, potential airway obstruction risks, and the patient and ability to tolerate treatment. Patients with Morquio syndrome might have anatomical abnormalities that affect their airway. Dental treatment should be planned to ensure that the patient and airway is maintained during procedures. Consultation with an anesthesiologist might be necessary for certain cases. Due to dental abnormalities common in Morquio syndrome (such as malocclusion, overcrowding, and dental caries), specialized dental care by professionals experienced in managing such cases is crucial. Orthodontic treatment and dental restorations may be needed to address these issues. Dental procedures might require anesthesia, and considering the potential airway complications, selecting the appropriate anesthesia technique is vital. This decision should be made in consultation with an anesthesiologist familiar with the condition. In summary, optimizing dental treatment for Morquio syndrome patients involves a comprehensive understanding of the condition and impact on dental health, careful planning, specialized dental care, consideration of potential airway complications, and ensuring patient comfort throughout the treatment process. Collaboration among various healthcare professionals, including dentists, orthodontists, anesthesiologists, and other specialists, is crucial to provide the best possible care for these individuals.

 Keywords: Mucopolysaccharidoses (MPS); Glycosaminoglycans (GAGs); Morquio Syndrome (Mucopolysaccharidosis IVA)

1. Lachman RS., et al. “Mucopolysaccharidosis IVA (Morquio A syndrome) and VI (Maroteaux-Lamy syndrome): under-recognized and challenging to diagnose”. Skeletal Radiology3 (2014): 359-369.
2. de Santana Sarmento DJ., et al. “Mucopolysaccharidosis: radiographic findings in a series of 16 cases”. Oral Surgery, Oral Medicine, Oral Pathology Oral Radiology 6 (2015): e240-e246.
3. Kircher S., et al. “Mucopolysaccharidoses - a guide for physicians and parents”. UNI-MED Verlag AG, International Medical Publishers, London, Boston, Printed in Europe (2007).
4. Garn SM and Hurme VO. “Dental defects in three siblings afflicted with Morquio’s disease”. British Dental Journal 93 (1952): 210-212.
5. James A., et al. “The Oral Health Needs of Children, Adolescents and Young Adults Affected by a Mucopolysaccharide Disorder”. In: SSIEM, editor. JIMD Reports - Case and Research Reports, 2011/2 [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg (2011): 51-58.
6. Guven G., et al. “Mucopolysaccharidosis type I (Hurler syndrome): oral and radiographic findings and ultrastructural/chemical features of enamel and dentin”. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 1 (2008): 72-78.
7. Lustmann J. “Dentinoenamel junction area in primary teeth affected by Morquio’s syndrome”. Journal of Dental Research 3 (1978): 475-479.
8. Fonseca FRA., et al. “Patients with mucopolysaccharidosis have tendencies towards vertical facial growth”. Journal of Oral and Maxillofacial Surgery 12 (2014): 2539-2546.
9. Kinirons MJ and Nelson J. “Dental findings in mucopolysaccharidosis type IV A (Morquio’s disease type A)”. Oral Surgery, Oral Medicine, Oral Pathology 2 (1990): 176-179.
10. RéLLING I., et al. “Dental findings in three siblings with Morquio’s syndrome”. International Journal of Paediatric Dentistry 3 (1999): 219-224.
11. Langer LO and Carey LS. “The roentgenographic features of the KS mucopolysaccharidosis of Morquio (Morquio-Brailsford’s disease)”. American Journal of Roentgenology 1 (1966): 1-20.
12. Levin LS., et al. “Oral findings in the Morquio syndrome (mucopolysaccharidosis IV)”. Oral Surgery, Oral Medicine, Oral Pathology 3 (1975): 390-395.
13. Fujimoto A and Horwitz AL. “Biochemical defect of non-keratan-sulfate-excreting Morquio syndrome”. American Journal of Medical Genetics 2 (1983): 265-273.
14. Hecht JT., et al. “Mild manifestations of the Morquio syndrome”. American Journal of Medical Genetics 2 (1984): 369-371.
15. Beck M., et al. “Heterogeneity of Morauio disease”. Clinical Genetics 4 (1986): 325-331.
16. Omatsu S., et al. “Enzyme replacement therapy in a murine model of Morquio A syndrome”. Human Molecular Genetics 6 (2008): 815-824.
17. Lee NH., et al. “Clinical, radiologic, and genetic features of Korean patients with Mucopolysaccharidosis IVA”. Korean Journal of Pediatrics 11 (2012): 430-437.
18. Hendriksz CJ., et al. “International guidelines for the management and treatment of Morquio A syndrome: Morquio A syndrome management guidelines”. American Journal of Medical Genetics Part A 1 (2015): 11-25.
19. Lavery C and Hendriksz C. “Mortality in Patients with Morquio Syndrome A”. In Berlin, Heidelberg: Springer Berlin Heidelberg (2014).